Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

← catalyst calendar

NCT05027906 · readout ≤ 165 d

Sponsored by Eledon Pharmaceuticals (industry) · ELDN — their whole pipeline →.

Phase

Phase 1/2

Status

Recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

48estimated

Sites

Countries

Australia, Brazil, Canada +2

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2022-02-18

actual

When the study began enrolling

Primary completion

Jan 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jan 2027

estimated

The whole study's end, after follow-up

First posted

2021-08-30

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2025-06-29

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Prevention of Rejection in Kidney Transplant

Intervention

Drug: AT-1501

Primary outcomes

what the primary-completion date above is the date OF

Safety Incidences

measured Through study completion, an average up to 20 months

Pharmacokinetic- PK profile